Low-Dose Naltrexone ("LDN") in Crohn's

Low-Dose Naltrexone ("LDN") in Crohn's

Link | View Protocol | Edit Protocol
Therapeutic Area: Gastrointestinal System
12

Days Left to
Participate
Number of Contributors: 56
Target Completion Date: June 2013
Project Progress: progress bar
Protocol Builder Results: Click here to view report

Why LDN in Crohn's disease?

  • The unmet medical need in Crohn's Disease remains high. Current medications are only modestly effective; some have severe side effects.
  • Naltrexone is an opiate receptor antagonist that has been used safely in hundreds of thousands of patients worldwide for treatment of drug and alcohol abuse.
  • Anecdotal evidence of efficacy in Crohn's Disease has been reported, but compelling data from a recently-completed randomized placebo-controlled trial is additional reason to study LDN.

Please join us in designing an innovative clinical study of LDN in Crohn's disease!

View Project Background (PDF )PDF

View Project Disclaimer (PDF) PDF

Protocol Challenges

Here's how you can get involved right now:

The Protocol Challenges give you input into the team designing the clinical trial.

Please login or register so that you can contribute your knowledge to our protocols.

right check
Marc Foster

Project Coordinator


Mr. Marc
Foster
Ms. Lisa Abrams

Patient Community Manager


Ms. Lisa Abrams MS

Patients & Families - Get Involved!

Not sure how to contribute? Click a link below for guidance.

Get Started Now !

 Recent Forum Posts